Edition:
United States

Agenus Inc (AGEN.OQ)

AGEN.OQ on NASDAQ Stock Exchange Capital Market

2.70USD
18 Jun 2018
Change (% chg)

-- (--)
Prev Close
$2.70
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
394,025
52-wk High
$6.19
52-wk Low
$2.70

Chart for

About

Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast... (more)

Overall

Beta: 1.58
Market Cap(Mil.): $270.49
Shares Outstanding(Mil.): 100.18
Dividend: --
Yield (%): --

Financials

  AGEN.OQ Industry Sector
P/E (TTM): -- 240.92 34.18
EPS (TTM): -1.57 -- --
ROI: -118.06 -5.87 13.17
ROE: -- -7.71 15.15

BRIEF-Agenus Inc Files Prospectus Supplement Relates To Sale Of Up To 20 Mln Shares Of Co

* AGENUS INC FILES PROSPECTUS SUPPLEMENT RELATES TO ISSUANCE, SALE OF UP TO 20 MILLION SHARES OF CO'S COMMON THROUGH B. RILEY FBR INC - SEC FILING Source text: (https://bit.ly/2rCkYJ1) Further company coverage:

May 11 2018

BRIEF-Agenus Inc Says Terminated Controlled Equity Offering Sales Agreement With Cantor Fitzgerald & Co

* AGENUS INC - ON MAY 7 TERMINATED CONTROLLED EQUITY OFFERING(SM)SALES AGREEMENT WITH CANTOR FITZGERALD & CO

May 08 2018

BRIEF-Agenus Q1 Loss Per Share $0.53

* AGENUS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 07 2018

BRIEF-Agenus Reports Q4 Loss Per Share $0.35

* AGENUS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Mar 15 2018

BRIEF-Agenus Inc Files For Sale Of Up 10 Mln Shares Of Common Stock By Selling Stockholders

* AGENUS INC FILES FOR SALE OF UP 10 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text (http://bit.ly/2n84why) Further company coverage:

Jan 24 2018

BRIEF-Agenus Announces Combination Clinical Trials Of Anti-CTLA4 & Anti-PD1

* AGENUS ANNOUNCES COMBINATION CLINICAL TRIALS OF ITS ANTI-CTLA4 (AGEN1884) & ANTI-PD1 (AGEN2034)

Jan 22 2018

BRIEF-Agenus Announces $230 Mln Royalty Monetization With Healthcare Royalty Partners

* AGENUS INC. ANNOUNCES $230 MILLION ROYALTY MONETIZATION WITH HEALTHCARE ROYALTY PARTNERS

Jan 08 2018

Earnings vs. Estimates